Transverse myelitis after anti-CD19 directed CAR T cell therapy for relapsed large B cell lymphoma
EJHaem
.
2021 Dec 6;3(1):223-227.
doi: 10.1002/jha2.286.
eCollection 2022 Feb.
Authors
Semira Sheikh
1
,
Sepideh Mokhtari
2
,
Jeffrey A Silverman
3
,
Kayla Reid
4
,
Rawan Faramand
5
,
Marco L Davila
6
,
Norman Franke
7
,
Frederick L Locke
6
,
Michael D Jain
6
,
Daniel Wong
8
,
John G Kuruvilla
7
Affiliations
1
Division of Medical Oncology and Hematology University Health Network Toronto Canada.
2
Department of Neuro-Oncology Moffitt Cancer Center Tampa Florida USA.
3
Department of Hematology North York General Hospital Toronto Canada.
4
Department of Hematology Moffitt Cancer Center Tampa Florida USA.
5
Department of Malignant Hematology Moffitt Cancer Center Tampa Florida USA.
6
Department of Blood & Marrow Transplant and Cellular Immunotherapy Moffitt Cancer Center Tampa Florida USA.
7
Division of Medical Oncology and Hematology Princess Margaret Hospital Toronto Canada.
8
Department of Neurology North York General Hospital Toronto Canada.
PMID:
35846190
PMCID:
PMC9175700
DOI:
10.1002/jha2.286
No abstract available
Keywords:
CAR T cell therapy; ICANS; neurotoxicity; transverse myelitis.
Publication types
Case Reports